Systematic review / meta-analysis / 2021
Current evidence does not support resveratrol supplementation for managing cardiometabolic risk factors in patients with type 2 diabetes, MetS, or NAFLD.
An umbrella review analyzed meta-analyses of randomized controlled trials examining resveratrol supplementation compared to control groups in patients with type 2 diabetes, metabolic syndrome, and NAFLD. While resveratrol showed beneficial effects on some markers (such as blood pressure, lipids, glycemic control, and waist circumference), the magnitude of effect was generally trivial, evidence certainty was very low to low, or trials were too few. Resveratrol showed a clinically important short-term (<12 weeks) reduction in HbA1c (mean difference: -1.05%, 95% CI: -2.09% to -0.02%; n = 6; moderate certainty), though evidence overall does not support supplementation for cardiometabolic management.
- Study type
- Umbrella review of meta-analyses of randomized controlled trials
- Who was studied
- Patients with type 2 diabetes (n=1476), metabolic syndrome (n=727), and NAFLD (n=271)
- What was measured
- Cardiometabolic risk factors including blood pressure, lipid profile, glycemic control, insulin resistance, waist circumference, and inflammation markers
THE PAPER
The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials.
Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. Am J Clin Nutr, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.